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Mortality in patients with heart failure and reduced ejec-tion fraction (HFrEF) has improved over time because 
of the step-wise introduction of a variety of pharmacological 
treatments. For years, recommended treatments for patients 
with HFrEF included the combination of an angiotensin-con-
verting enzyme inhibitor (ACEI; or an angiotensin II receptor 
blocker [ARB] if an ACEI is not tolerated), a β-blocker (BB), 
and a mineralocorticoid receptor antagonist (MRA).1 Despite 
these recommended treatments being evidence based, the 
mortality rate for patients with HFrEF remains high.2–4
Sacubitril/valsartan, a first-in-class angiotensin receptor–
neprilysin inhibitor (ARNI), was recommended as a new treat-
ment option for patients with HFrEF in the 2016 European 
Society for Cardiology guidelines5 and the 2016 American 
College of Cardiology/American Heart Association guide-
lines.6 These recommendations were based on the results of 
the PARADIGM-HF trial (Prospective Comparison of ARNI 
With ACE to Determine Impact on Global Mortality and 
Morbidity in Heart Failure), which showed sacubitril/valsar-
tan to be superior to enalapril in reducing the risks of car-
diovascular and all-cause mortality when added to a BB (in 
most patients) and a MRA (in many), as well as a diuretic and 
digoxin.7
See Clinical Perspective
There are now 5 types (ACEI, ARB, BB, MRA, and 
ARNI) of life-saving pharmacological therapies available to 
treat patients with HFrEF. Given that most trials in HFrEF 
have compared newer agents to placebo, which has included 
alternative background treatments as recommendations have 
evolved, there is a need to understand how the efficacy of these 
individual treatments and various combinations compare in 
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Background—Treatments that reduce mortality and morbidity in patients with heart failure with reduced ejection fraction, 
including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blockers (BB), 
mineralocorticoid receptor antagonists (MRA), and angiotensin receptor–neprilysin inhibitors (ARNI), have not been 
studied in a head-to-head fashion. This network meta-analysis aimed to compare the efficacy of these drugs and their 
combinations regarding all-cause mortality in patients with heart failure with reduced ejection fraction.
Methods and Results—A systematic literature review identified 57 randomized controlled trials published between 1987 
and 2015, which were compared in terms of study and patient characteristics, baseline risk, outcome definitions, and the 
observed treatment effects. Despite differences identified in terms of study duration, New York Heart Association class, 
ejection fraction, and use of background digoxin, a network meta-analysis was considered feasible and all trials were 
analyzed simultaneously. The random-effects network meta-analysis suggested that the combination of ACEI+BB+MRA 
was associated with a 56% reduction in mortality versus placebo (hazard ratio 0.44, 95% credible interval 0.26–0.66); 
ARNI+BB+MRA was associated with the greatest reduction in all-cause mortality versus placebo (hazard ratio 0.37, 
95% credible interval 0.19–0.65). A sensitivity analysis that did not account for background therapy suggested that ARNI 
monotherapy is more efficacious than ACEI or ARB monotherapy.
Conclusions—The network meta-analysis showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their 
combinations were better than the treatment with placebo in reducing all-cause mortality, with the exception of ARB 
monotherapy and ARB plus ACEI. The combination of ARNI+BB+MRA resulted in the greatest mortality reduction. 
(Circ Heart Fail. 2017;10:e003529. DOI: 10.1161/CIRCHEARTFAILURE.116.003529.)
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2  Burnett et al  NMA of the Efficacy of Drug Treatments for HFrEF 
terms of all-cause mortality. If all trials have at least one inter-
vention in common with another, it is possible to develop a 
network of randomized controlled trials (RCTs), allowing for 
indirect comparisons of interventions not studied in a head-
to-head fashion using network meta-analysis (NMA).8 The 
validity of any NMA relies on whether there are systematic 
differences across RCTs in terms of patient or disease charac-
teristics that are treatment effect modifiers.8–11 Consequently, 
it is important to identify the relevant network of RCTs and to 
assess the feasibility of performing a valid NMA.
The objective of this study was to systematically identify 
RCTs evaluating recommended drug classes and combinations 
for HFrEF in terms of all-cause mortality and to perform a valid 
NMA assessing the comparative efficacy of these therapies.
Methods
Identification and Selection of Studies
A systematic literature review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement.12 Medline, EMBASE, and Cochrane 
CENTRAL were searched to identify studies published between 
January 1987 and April 28, 2015. Search terms included a combi-
nation of free text and Medical Subject Heading terms (see Data 
Supplement). Two reviewers (H. Burnett and A. Earley) indepen-
dently screened citations against the following predefined selection 
criteria.
Population
Studies evaluating adults (aged ≥18 years) with chronic HFrEF (left 
ventricular ejection fraction <45%) and New York Heart Association 
class II–IV of varying etiology (ischemic and dilated cardiomyopa-
thy) who were outpatients were included. Studies were excluded 
if the entire study population had one of the following character-
istics, which are known to impact treatment response or all-cause 
mortality: (1) acute heart failure, (2) hospitalized, (3) New York Heart 
Association class I, (4) clinical comorbidity (eg, chronic obstructive 
pulmonary disease, diabetes mellitus, or renal failure), (5) coronary 
heart disease, (6) post-myocardial infarction, (7) ischemia, (8) idio-
pathic dilated cardiomyopathy, (9) elderly (aged >70 years), or (10) 
from country outside of North America or Europe. Studies that in-
cluded a proportion of patients with the characteristics described 
above were included.
Interventions
All guideline-recommended drug classes: ACEIs, BBs, ARBs, and 
MRAs and an ARNI, administered alone or in combination (see Table 
I in the Data Supplement for eligible drug molecules).
Comparators
Placebo or any intervention of interest of a different class; compari-
sons within the same class were excluded (eg, ACEI versus ACEI).
Outcomes
Death because of any cause reported as an efficacy or safety end 
point.
Study Design
Phase II or III RCTs published in English.
Data Extraction and Quality Assessment
For each included study, details were extracted on study design, pa-
tient characteristics, and interventions. The quality of the RCTs was 
assessed.13 For all-cause mortality, the total number of events was 
extracted for each arm, and the exposure time for each trial was ex-
tracted for the planned study duration, if reported, or else the mean or 
median follow-up time.
Feasibility Assessment
The feasibility of conducting a valid NMA was assessed using the 
process described by Cope et al,14 which involves an assessment 
of clinical heterogeneity in terms of the characteristics of the treat-
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Figure 1. Flow diagram. RCT indicates randomized controlled trials.
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differences within and across treatments in terms of baseline risk and 
the observed treatment effects. The following factors were identified 
a priori as potential treatment effect modifiers: use of concomitant 
treatments (eg, digoxin), duration of follow-up, year of publication, 
severity of included patients (eg, New York Heart Association class 
and left ventricular ejection fraction), heart failure etiology (eg, isch-
emic versus nonischemic), and history of myocardial infarction.
Network Meta-Analysis
Bayesian NMA models were used to simultaneously synthesize the re-
sults of the included studies and to obtain relative treatment effects.11,15–17 
NMA within the Bayesian framework involves data, a hierarchical 
model or likelihood function with parameters, and prior distributions.18 
The model relates data from RCTs to parameters reflecting the (pooled) 
relative treatment effect of each intervention compared with the refer-
ence treatment (eg, placebo). Data sets for the model were based on 
the reported number of patients with an event at the end of the trial per 
arm, the total number of patients randomized per arm, and the mean 
follow-up duration of the trial. The log mean follow-up time was used 
to transform the probability of an event into a constant rate for each trial 
arm by assuming an underlying Poisson process, and a complemen-
tary log–log (cloglog) link was used to model the event rates.10 Outputs 
from the model were presented as hazard ratios (HRs) for each treat-
ment versus placebo. Goodness of fit was assessed using the residual 
deviance and deviance information criterion.19 Results of the random-
effects model were presented unless the fixed-effect model resulted in 
a more parsimonious model. Noninformative prior distributions were 
used: a normal distribution for the difference measures (mean 0, var 
104) and a uniform distribution for between-study standard deviation 
(range 0–5). The analysis was performed with published codes10 using 
OpenBuGS software20 (2 chains were used, including 100 000 burn-in 
iterations followed by 200 000 iterations).
Results of the NMA reflect the posterior distributions of the mod-
el parameters. In addition to point estimates of the HRs, 95% credible 
intervals (CrI), reflecting the range of true underlying effects with 
Figure 2. Network diagram of treatment classes and combinations reporting all-cause mortality. ACEI indicates angiotensin-converting 
enzyme inhibitor; ARB, angiotensin-II receptor blocker; AREA-IN CHF, Anti-Remodelling Effect of Canrenone in Patients With Mild Chronic 
Heart Failure; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta blocker; BEST, Beta-Blocker Evaluation of Survival Trial; CAR-
MEN, The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial; CASSIS, Czech and Slovak Spirapril Intervention 
Study; CHARM-added, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity–Added; CHARM-alternative, 
Candesartan in Heart Failure–Assessment of Mortality and Morbidity Alternative; CIBIS, Cardiac Insufficiency Bisoprolol Study; CONSEN-
SUS, Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival; 
ELITE, Evaluation of Losartan in the Elderly Study; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart 
Failure; ENECA, Efficacy of Nebivolol in the Treatment of Elderly Patients With Chronic Heart Failure as Add-On Therapy to ACE Inhibi-
tors or Angiotensin II Receptor Blockers, Diuretics, and/or Digitalis; FEST, Fosinopril Efficacy/Safety Trial; HEAVEN, Heart Failure Valsartan 
Exercise Capacity Evaluation; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; MHFT, Munich Mild 
Heart Failure Trial; MIC, Metoprolol in Patients With Mild to Moderate Heart Failure: Effects on Ventricular Function and Cardiopulmonary 
Exercise Testing; MOCHA, Multicenter Oral Carvedilol Heart Failure Assessment; MRA, mineralocorticoid receptor antagonist; PARADIGM-
HF, Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) With ACEI (Angiotensin–Converting–Enzyme Inhibitor) to 
Determine Impact on Global Mortality and Morbidity in Heart Failure; PLBO, placebo; PRECISE, Prospective Randomized Evaluation of 
Carvedilol on Symptoms and Exercise; RALES, Randomized Aldactone Evaluation Study; REPLACE, Replacement of Angiotensin Convert-
ing Enzyme Inhibition; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunction; SOLVD-prevent, Studies of Left 
Ventricular Dysfunction–Prevention Trial; SOLVD-treat, Studies of Left Ventricular Dysfunction–Treatment Trial; SPICE, Study of Patients 
Intolerant of Converting Enzyme Inhibitors; STRETCH, Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart 
Failure; SYMPOXYDEX, Sympathetic and Oxydative Stress Kredex Study; and Val-HeFT, Valsartan Heart Failure Trial.7,21–77
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95% probability, are presented. The rank probabilities and expected 
rank for all treatments are presented, as well as the probability that 
one treatment is better than a specific comparator.11 Means, standard 




Fifty-seven RCTs were included (Figure 1) and are described in 
Table II in the Data Supplement.7,21–77 The majority were multi-
center, double-blind, placebo-controlled trials, including between 
28 and 8399 patients with a mean follow-up duration ranging 
from 8 weeks to 4 years. The treatment classes assessed included 
ACEI, BB, ARB, MRA, and ARNI. Patients were generally 
allowed concomitant therapies, such as diuretics, digoxin, and 
nitrates, as well as other permitted concomitant treatment classes.
Network of Evidence
In the network of connected RCTs (Figure 2), the thickness 
of the lines corresponds to the number of trials included per 
treatment comparison. The evidence was centralized around 
placebo and ACEI, with most RCTs informing the comparison 
of ACEI+BB versus ACEI. The treatment combination with 
ARNI was informed by a single RCT.
Differences Within or Between Direct Treatment 
Comparisons That May Modify Treatment Effect
Treatment Definitions
There was a wide range in the types of individual and concom-
itant treatments (Table III in the Data Supplement). In fact, few 
trials included a true placebo arm because study patients were 
often permitted to receive or continue to receive the standard of 
care in addition to study drugs. An increase in the use of com-
bination therapies was observed over the years, with the earli-
est trials being focused on ACEIs versus placebo, followed by 
the addition of BB (ACEI+BB versus ACEI studies), and then 
ARB and MRA containing therapies around the same time 
after their introduction. The combination ACEI+BB+MRA 
was first evaluated in 2002 compared with ACEI+BB. To take 
into account concomitant drug classes of interest and more 
accurately define placebo in the analysis, treatments were cat-

































Figure 3. Sensitivity analysis evidence network of ARNI, ACEI, ARB and placebo for all-cause mortality ignoring background treatments. 
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor-neprilysin 
inhibitor; CASSIS, Czech and Slovak Spirapril Intervention Study; CHARM-alternative, Candesartan in Heart Failure–Assessment of Mor-
tality and Morbidity Alternative; CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; ELITE, Evaluation of Losartan 
in the Elderly Study; FEST, Fosinopril Efficacy/Safety Trial; HEAVEN, Heart Failure Valsartan Exercise Capacity Evaluation; MHFT, Munich 
Mild Heart Failure Trial; PARADIGM-HF, Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) With ACEI (Angio-
tensin–Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure; PLBO, placebo; REPLACE, 
Replacement of Angiotensin Converting Enzyme Inhibition; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunc-
tion; SOLVD-prevent, Studies of Left Ventricular Dysfunction–Prevention Trial; SOLVD-treat, Studies of Left Ventricular Dysfunction–Treat-
ment Trial; SPICE, Study of Patients Intolerant of Converting Enzyme Inhibitors; and STRETCH, Symptom, Tolerability, Response to 
Exercise Trial of Candesartan Cilexetil in Heart Failure.7,21–45
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patients in the study were receiving it at baseline. Specifically, 
if >50% of the trial patients received a concomitant drug of 
interest in the systematic review (eg, BB), the treatment was 
described as a combination therapy (the study drug class+the 
concomitant drug class(es), eg, ACEI+BB versus BB) in the 
analysis. The threshold to define concomitant therapy was 
based on expert opinion and involved an evaluation of differ-
ent thresholds ranging from 50% to 60%.78
When the permitted concomitant drug was ACEI or ARB 
and the publication failed to report the distribution of patients 
receiving each class, it was assumed that patients were tak-
ing ACEI (Table IV in the Data Supplement). A sensitivity 
A B
Figure 4. Distribution of potential treatment effect modifiers: A, Duration of follow-up7,21–77; B, NYHA class at baseline7,21–77; C, LVEF at 
baseline.7,21–77 AREA-IN CHF indicates Anti-Remodelling Effect of Canrenone in Patients With Mild Chronic Heart Failure; BEST, Beta-
Blocker Evaluation of Survival Trial; CARMEN, The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial; CASSIS, 
Czech and Slovak Spirapril Intervention Study; CHARM-added, Candesartan in Heart Failure: Assessment of Reduction in Mortality and 
Morbidity–Added; CHARM-alternative, Candesartan in Heart Failure–Assessment of Mortality and Morbidity Alternative; CIBIS, Cardiac 
Insufficiency Bisoprolol Study; CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS, Carvedilol Pro-
spective Randomized Cumulative Survival; ELITE, Evaluation of Losartan in the Elderly Study; EMPHASIS-HF, Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart Failure; ENECA, Efficacy of Nebivolol in the Treatment of Elderly Patients With Chronic Heart 
Failure as Add-On Therapy to ACE Inhibitors or Angiotensin II Receptor Blockers, Diuretics, and/or Digitalis; FEST, Fosinopril Efficacy/
Safety Trial; HEAVEN, Heart Failure Valsartan Exercise Capacity Evaluation; LVEF, left ventricular ejection fraction; MERIT-HF, Metopro-
lol CR/XL Randomised Intervention Trial in Congestive Heart Failure; MHFT, Munich Mild Heart Failure Trial; MIC, Metoprolol in Patients 
With Mild to Moderate Heart Failure: Effects on Ventricular Function and Cardiopulmonary Exercise Testing; MOCHA, Multicenter Oral 
Carvedilol Heart Failure Assessment; NR, not reported; NYHA, New York Heart Association; PARADIGM-HF, Prospective (Continued )  
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analysis was also performed that ignored concomitant thera-
pies and evaluated how ARNI monotherapy was compared 
with ACEI and ARB monotherapies (Figure 3).7,21–45
Despite some variation in individual treatment doses and 
schedules (Table V in the Data Supplement), all analyses 
assumed that treatments within a given class were compara-
ble in terms of their ability to prevent death. All trials were 
included, even though some variation was also observed in the 
proportion of patients receiving concomitant digoxin.
Outcome Definition
All-cause mortality is an objective end point and is usually 
reported as a primary or secondary outcome, although the 
NMA also included 28 trials that reported mortality as an 
adverse event or a reason for study withdrawal (Figure 4A). 
Because the quality of these 28 studies did not differ greatly 
from that of the other included trials, the broadest evidence 
base was included.
Study and Patient Characteristics
The RCTs were broadly comparable in terms of study design, 
despite a wide range in publication year (1987–2014). There 
were some differences in study quality, although overall the 
risk of bias was low (Figure I in the Data Supplement). Given 
the differences in the duration of follow-up across trials (Fig-
ure 4A), patient exposure was accounted for in the analysis.
Enrolled patients were predominantly male (mean 76%, 
range 49%–90%) and between the ages of 52 and 73 years 
(mean 62 years; Table II in the Data Supplement). Most 
patients were classified as New York Heart Association class 
II–III (mean 86%), although 8 (14%) trials included a propor-
tion of patients in class I and 36 (63%) trials included patients 
in class IV (Figure 4B). Baseline left ventricular ejection frac-
tion ranged between 15% and 40% (mean 27%; Figure 4C). 
In terms of heart failure etiology, 57% of the included patients 
had ischemic heart disease (range 10%–83%). It was not 
possible to consistently assess differences in the duration of 
heart failure, the use of pacemakers or implantable devices, 
or the history of myocardial infarction because of inconsistent 
reporting.
Baseline Risk and Observed Treatment Effects
Given variation in publication year across trials, differences 
attributable to changes in clinical practice over time may result 
in differences in baseline risk that could influence the treatment 
effect. However, the network of evidence does not provide a 
well-connected common comparator (placebo or standard of 
care), partly because of the treatment categorization based on 
concomitant therapy used to account for differences in placebo. 
Figure II in the Data Supplement reports the rates of death per 
patient year for all treatment arms and RCTs by publication 
year. Although the rates varied across included RCTs, it was 
unclear whether these differences were driven by changes in 
practice over time or acted as a treatment effect modifier.
Network Meta-Analysis Results
All identified RCTs were included in the NMA and provided 
comparative evidence on all-cause mortality in patients with 
HFrEF.
Figure 4 Continued. Comparison of ARNI (Angiotensin 
Receptor–Neprilysin Inhibitor) With ACEI (Angiotensin–Con-
verting–Enzyme Inhibitor) to Determine Impact on Global 
Mortality and Morbidity in Heart Failure; PRECISE, Prospec-
tive Randomized Evaluation of Carvedilol on Symptoms and 
Exercise; RALES, Randomized Aldactone Evaluation Study; 
REPLACE, Replacement of Angiotensin Converting Enzyme 
Inhibition; RESOLVD, Randomized Evaluation of Strategies for 
Left Ventricular Dysfunction; SOLVD-prevent, Studies of Left 
Ventricular Dysfunction–Prevention Trial; SOLVD-treat, Stud-
ies of Left Ventricular Dysfunction–Treatment Trial; SPICE, 
Study of Patients Intolerant of Converting Enzyme Inhibitors; 
STRETCH, Symptom, Tolerability, Response to Exercise Trial 
of Candesartan Cilexetil in Heart Failure; SYMPOXYDEX, 
Sympathetic and Oxydative Stress Kredex Study; and Val-
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Table 1 presents the results of the random effect NMA for all 
head-to-head comparisons and illustrates the HRs, the 95% CrIs, 
and the probability of a treatment being better than the comparator. 
We found significant between-study heterogeneity in the network 
of evidence (SD 0.18, 95% CrI 0.06–0.35; Table 1), which was 
expected given the differences observed in the included studies.
Figure 5 illustrates the HRs for each treatment class ver-
sus placebo for all-cause mortality. The combination of 
ACEI+BB+MRA was associated with a 56% reduction in 
mortality versus placebo (HR 0.44, 95% CrI 0.26–0.66), while 
ARNI+BB+MRA was associated with the greatest reduction in 
all-cause mortality versus placebo (HR 0.37, 95% CrI 0.19–0.65). 
Figure III in the Data Supplement summarizes the rank probabili-
ties for all interventions.
Table 2 presents the results from the sensitivity analysis that 
ignored concomitant therapies and evaluated how ARNI mono-
therapy was compared with ACEI and ARB monotherapies. The 
random-effects model suggests that all active treatments are 
Table 1. Results of Random Effect Network Meta-Analysis for All-Cause Mortality Rates: Difference in Intervention Versus the 
Comparator, 95% Credible Intervals (CrI), and Probability That the Intervention Is Better Than the Comparator [P(better)]
Intervention
Comparator
PLBO ACEI ARB BB ACEI+BB
PLBO
  Estimate (95% CrI) 1 (1,1) 1.203 (0.989–1.512) 1.132 (0.793–1.65) 1.752 (1.067–3.041) 1.758 (1.382–2.424)
  P(better) NA 0.03 0.23 0.01 0.00
ACEI
  Estimate (95% CrI) 0.831 (0.661–1.011) 1 (1–1) 0.941 (0.679–1.292) 1.454 (0.92–2.38) 1.462 (1.255–1.783)
  P(better) 0.97 NA 0.66 0.05 0.00
ARB
  Estimate (95% CrI) 0.883 (0.606–1.261) 1.063 (0.774–1.473) 1 (1–1) 1.548 (0.886–2.8) 1.552 (1.103–2.31)
  P(better) 0.77 0.34 NA 0.06 0.01
BB
  Estimate (95% CrI) 0.571 (0.329–0.937) 0.688 (0.42–1.087) 0.646 (0.357–1.129) 1 (1–1) 1.008 (0.615–1.633)
  P(better) 0.99 0.95 0.94 NA 0.49
ACEI+BB
  Estimate (95% CrI) 0.569 (0.413–0.724) 0.684 (0.561–0.797) 0.644 (0.433–0.906) 0.992 (0.612–1.626) 1 (1–1)
  P(better) 1.0 1.0 0.99 0.51 NA
ACEI+ARB
  Estimate (95% CrI) 0.827 (0.505–1.243) 0.994 (0.658–1.448) 0.935 (0.548–1.514) 1.441 (0.789–2.672) 1.448 (0.964–2.232)
  P(better) 0.84 0.52 0.62 0.11 0.03
ARB+BB
  Estimate (95% CrI) 0.472 (0.23–0.855) 0.567 (0.293–1.002) 0.534 (0.254–1.021) 0.828 (0.518–1.215) 0.831 (0.435–1.493)
  P(better) 0.99 0.97 0.97 0.85 0.74
ACEI+MRA
  Estimate (95% CrI) 0.574 (0.348–0.908) 0.69 (0.448–1.058) 0.648 (0.378–1.103) 1.003 (0.54–1.935) 1.004 (0.653–1.649)
  P(better) 0.99 0.96 0.95 0.50 0.49
ACEI+ARB+BB
  Estimate (95% CrI) 0.518 (0.308–0.795) 0.623 (0.397–0.926) 0.586 (0.334–0.97) 0.903 (0.486–1.68) 0.908 (0.614–1.358)
  P(better) 1.0 0.99 0.98 0.64 0.72
ACEI+BB+MRA
  Estimate (95% CrI) 0.44 (0.264–0.661) 0.53 (0.342–0.762) 0.498 (0.286–0.804) 0.767 (0.417–1.397) 0.773 (0.535–1.091)
  P(better) 1.0 1.0 1.0 0.81 0.94
ARNI+BB+MRA
  Estimate (95% CrI) 0.372 (0.189–0.647) 0.448 (0.24–0.758) 0.421 (0.206–0.774) 0.648 (0.308–1.329) 0.652 (0.371–1.11)
  P(better) 1.0 1.0 0.99 0.89 0.95
(Continued )
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likely to be more efficacious than placebo, although with more 
uncertainty than the base case analysis. The sensitivity analy-
sis showed that in comparison to placebo, ARNI was associated 
with a 29% reduction in mortality (HR 0.71, 95% CrI 0.39–
1.17); ACEI, a 16% reduction (HR 0.84, 95% CrI 0.65–1.01); 
and ARB, a 12% reduction (HR 0.88, 95% CrI 0.65–1.17).
Discussion
New trials build on the evidence from previous trials and 
therefore, test new drugs in addition to existing ones; as 
a result, it becomes increasingly difficult for clinicians to 
maintain a perspective on the relative efficacy of the treat-
ments they are advised to use or to fully appreciate the 
cumulative benefit of combining treatments. To provide 
this perspective, the relative efficacy of recommended drug 
classes and combinations in reducing mortality of HFrEF 
were estimated. This is the first NMA to consider the total-
ity of RCT evidence for recommended treatment classes and 
combinations, including 57 trials conducted over the past 30 




ACEI+ARB ARB+BB ACEI+MRA ACEI+ARB+BB ACEI+BB+MRA ARNI+BB+MRA
PLBO
  Estimate (95% CrI) 1.21 (0.804–1.979) 2.121 (1.169–4.354) 1.744 (1.101–2.874) 1.929 (1.258–3.244) 2.272 (1.513–3.791) 2.689 (1.545–5.303)
  P(better) 0.16 0.01 0.01 0.00 0.00 0.00
ACEI
  Estimate (95% CrI) 1.007 (0.691–1.521) 1.763 (0.998–3.415) 1.45 (0.945–2.232) 1.605 (1.08–2.518) 1.889 (1.312–2.925) 2.235 (1.319–4.166)
  P(better) 0.48 0.03 0.04 0.01 0.00 0.00
ARB
  Estimate (95% CrI) 1.07 (0.66–1.824) 1.871 (0.98–3.945) 1.542 (0.907–2.645) 1.707 (1.031–2.997) 2.009 (1.243–3.501) 2.378 (1.291–4.847)
  P(better) 0.38 0.03 0.05 0.02 0.00 0.01
BB
  Estimate (95% CrI) 0.694 (0.374–1.267) 1.207 (0.823–1.929) 0.997 (0.517–1.852) 1.107 (0.595–2.058) 1.304 (0.716–2.398) 1.543 (0.752–3.248)
  P(better) 0.89 0.15 0.50 0.36 0.19 0.11
ACEI+BB
  Estimate (95% CrI) 0.691 (0.448–1.037) 1.203 (0.67–2.299) 0.996 (0.607–1.532) 1.102 (0.736–1.63) 1.294 (0.917–1.87) 1.533 (0.901–2.696)
  P(better) 0.97 0.26 0.51 0.28 0.06 0.05
ACEI+ARB
  Estimate (95% CrI) 1 (1–1) 1.746 (0.883–3.743) 1.441 (0.787–2.537) 1.594 (0.944–2.734) 1.871 (1.111–3.326) 2.217 (1.148–4.567)
  P(better) NA 0.05 0.09 0.04 0.01 0.01
ARB+BB
  Estimate (95% CrI) 0.573 (0.267–1.132) 1 (1–1) 0.824 (0.368–1.655) 0.916 (0.427–1.838) 1.075 (0.517–2.146) 1.277 (0.551–2.847)
  P(better) 0.95 NA 0.71 0.60 0.42 0.26
ACEI+MRA
  Estimate (95% CrI) 0.694 (0.394–1.27) 1.213 (0.604–2.715) 1 (1–1) 1.106 (0.621–2.083) 1.299 (0.755–2.439) 1.541 (0.784–3.311)
  P(better) 0.91 0.29 NA 0.35 0.15 0.09
ACEI+ARB+BB
  Estimate (95% CrI) 0.627 (0.366–1.059) 1.092 (0.544–2.34) 0.904 (0.48–1.61) 1 (1–1) 1.174 (0.702–2.045) 1.392 (0.724–2.8)
  P(better) 0.96 0.40 0.65 NA 0.25 0.13
ACEI+BB+MRA
  Estimate (95% CrI) 0.534 (0.301–0.9) 0.93 (0.466–1.935) 0.77 (0.41–1.325) 0.852 (0.489–1.425) 1 (1–1) 1.187 (0.784–1.799)
  P(better) 0.99 0.58 0.85 0.75 NA 0.17
ARNI+BB+MRA
  Estimate (95% CrI) 0.451 (0.219–0.871) 0.783 (0.351–1.814) 0.649 (0.302–1.275) 0.718 (0.357–1.381) 0.843 (0.556–1.276) 1 (1–1)
  P(better) 0.99 0.74 0.91 0.87 0.83 NA
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta blocker; MRA, 
mineralocorticoid receptor antagonist; and PLBO, placebo.
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Our results provide insight regarding the comparative effi-
cacy of treatments for which no head-to-head trials exist and 
suggest that ARNI+BB+MRA and ACEI+BB+MRA are the 
most efficacious treatment combinations in terms of reduc-
ing all-cause mortality. These findings validate global guide-
lines, which recommend first-line treatment of HFrEF with 
ACEI+BB (ARB+BB for those unable to tolerate ACEI), fol-
lowed by the addition of an MRA as second-line therapy and 
ARNI to replace ACEI in patients able to tolerate ACEI (or 
ARB) that remain symptomatic.5,6
Our findings also illustrate the step-wise reductions in 
mortality made possible by the incremental use of combina-
tions of disease-modifying therapies. The NMA results sug-
gest that ARNI+BB+MRA is the most efficacious therapy, 
reducing all-cause mortality by 63% compared with placebo. 
The magnitude of this benefit represents substantial progress 
in terms of treatments developed over the last 30 years (since 
the first report of an ACEI treatment). Although this finding 
depends on a single trial, PARADIGM-HF was the largest 
trial in the network, representing 18 898 patient-years of treat-
ment exposure.7 It is also important to note that although BB 
monotherapy is included in the network and, therefore, can be 
compared with other monotherapies using NMA, data to sup-
port this comparison are based on 2 small, short-duration trials 
(CIBIS III [Cardiac Insufficiency Bisoprolol Study III]46 and 
CARMEN trial [Carvedilol and ACE-Inhibitor Remodelling 
Mild Heart Failure Evaluation]47). The majority of available 
evidence regarding the efficacy of BB therapy is based on stud-
ies where patients were also receiving an ACEI (and MRA in 
more recent trials).
Our study is the result of a comprehensive and detailed 
NMA performed jointly by clinicians and methodologists. The 
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Figure 5. Results of random effect net-
work meta-analysis for all-cause mortal-
ity: hazard ratios for intervention versus 
placebo for all-cause mortality and 95% 
credible intervals. ACEI indicates angio-
tensin-converting enzyme inhibitor; ARB, 
angiotensin-II receptor blocker; ARNI, 
angiotensin receptor-neprilysin inhibitor; 
BB, beta blocker; and MRA, mineralocor-
ticoid receptor antagonist.
Table 2. Results of Random Effect Sensitivity Analysis Network Meta-Analysis for All-Cause 
Mortality Rates: Difference in Intervention Versus the Comparator, 95% Credible Intervals (CrI), and 
Probability That the Intervention Is Better Than the Comparator [P(better)]
Intervention
Comparator
PLBO ACEI ARB ARNI
PLBO
  Estimate (95% CrI) 1 (1–1) 1.191 (0.995–1.537) 1.131 (0.856–1.545) 1.410 (0.854–2.558)
  P(better) NA 0.03 0.15 0.06
ACEI
  Estimate (95% CrI) 0.840 (0.651–1.005) 1 (1–1) 0.947 (0.699–1.234) 1.188 (0.716–1.967)
  P(better) 0.97 NA 0.69 0.15
ARB
  Estimate (95% CrI) 0.884 (0.647–1.169) 1.056 (0.810–1.430) 1 (1–1) 1.252 (0.719–2.279)
  P(better) 0.85 0.31 NA 0.13
ARNI
  Estimate (95% CrI) 0.709 (0.391–1.170) 0.842 (0.508–1.396) 0.799 (0.439–1.390) 1 (1–1)
  P(better) 0.94 0.85 0.87 NA
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor antagonist; ARNI, angiotensin receptor-
neprilysin inhibitor; and PLBO, placebo.
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available data and underlying assumptions have been clearly 
illustrated to allow other researchers and decision-makers to 
critically analyze each choice and to update the analysis using a 
different approach. The way this study categorized the recom-
mended drug combinations and concomitant drugs (eg, ACEIs, 
ARBs, BBs, and MRAs) reflects a methodological development 
necessary to assess the comparative efficacy of these treatment 
combinations. The threshold approach allowed for differences 
in placebo to be defined and yielded clinically meaningful 
results, with monotherapies being less effective than combi-
nation therapies and regimens, including 3 treatment classes 
likely to be most efficacious. The importance of this approach 
is highlighted by results of the sensitivity analysis where con-
comitant therapies were ignored: ARNI was associated with a 
29% reduction in mortality compared with placebo, whereas 
the base case illustrated a 63% reduction with the combina-
tion of ARNI+BB+MRA. The difference relates to definition 
of placebo (as well as ACEI and ARB arms) in the sensitiv-
ity analysis, which included a wide range of concomitant drugs 
(eg, in CHARM-alternative trial [Candesartan in Heart Failure–
Assessment of Mortality and Morbidity Alternative],43 an ARB 
versus placebo trial, 55% of patients were receiving a BB), 
which were ignored or in some cases pooled with true pla-
cebo studies. In the base case analysis, placebo more closely 
represents the baseline risk of the patient population of interest 
because treatments were categorized based on the study drugs 
and concomitant drugs of interest.
Overall, findings were generally consistent with other 
published (network) meta-analyses evaluating all-cause mor-
tality that compared monotherapies within a single class to 
placebo in addition to standard of care.79–85 A recent putative 
placebo analysis by McMurray et al86 found that ARNI was 
associated with a 28% reduction in all-cause mortality, which 
was similar to the sensitivity analysis performed that ignored 
background therapy (ie, 29% reduction in all-cause mortality).
Direct comparisons of results from other published stud-
ies are limited by differences in included studies and the clas-
sification of concomitant drugs, which were often ignored or 
led to the exclusion of several trials. Therefore, the attempt in 
the current study to classify trials based on the background 
therapies may provide more valid insight regarding treatment 
classes used in combination in clinical practice.
Limitations
One limitation was the identification of concomitant therapy, 
which was based on data reported at baseline, which may have 
differed from treatments used during follow-up and certainly 
varied across the included trials. In addition, we assumed a 
class-effect, that is, all drugs in the same pharmacological 
class had similar efficacy, which may not be true. The same 
consideration applies to the dose of treatments used.
Most notably, differences were identified in terms of study 
duration, which may imply differences in the study purpose 
or type of mortality analysis. The length of follow-up in each 
trial was accounted for in the analysis assuming a propor-
tional hazards model, which allowed for an assessment of the 
broadest evidence base. A comparison of alternative scales 
and statistical models may be of interest to explore alternative 
underlying assumptions and the consistency of direct and 
indirect evidence.
Despite differences identified, no inconsistencies were 
identified, and adjustment for patient characteristics did not 
have substantial impact on the results. However, it should be 
recognized that there is a risk of ecological bias as study-level 
data were used to estimate the treatment effects. Individual 
patient data would be required to better explore differences 
in treatment effect modifiers.9,11,87 In addition, some informa-
tion was not consistently reported across the trials, limiting 
either the assessment of potential differences or the potential 
to adjust for differences (ie, duration of heart failure, etiol-
ogy, use of devices, or history of myocardial infarction).
To our knowledge, this review includes the broadest evi-
dence base. However, generalizability may be limited by 
including only English language studies and by excluding 
studies enrolling patients exclusively outside of North America 
and Europe. Based on the available data, it was not possible 
to assess some comparisons, such as MRA versus placebo, as 
well as the combination of a BB and MRA versus placebo. 
Although this study provides insight regarding all-cause mor-
tality for patients with HFrEF, other important efficacy and 
safety outcomes should also be considered by decision-mak-
ers, including death because of cardiovascular causes and heart 
failure, hospitalizations, and health-related quality of life.
Conclusions
This report provides a comprehensive analysis of the com-
parative efficacy of the individual drug classes and combina-
tions known to reduce mortality in patients with HFrEF. It 
was possible to pool and indirectly compare evidence from 
RCTs published over the last 34 years using NMA, providing 
insight into treatment comparisons in the absence of head-to-
head trials. The threshold approach used to account for con-
comitant therapy provides a more accurate representation of 
the treatment comparisons evaluated in RCTs, often reflecting 
standard of care at the time. Our results show that the most 
efficacious combinations for reducing all-cause mortality are 
in line with the most recent guideline recommendations.
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CLINICAL PERSPECTIVE
Over the past 30 years, much progress has been made regarding the treatment of patients with heart failure and reduced ejec-
tion fraction. Mortality has reduced over time, and there are now 5 main classes of life-saving pharmacological therapies 
recommended for the treatment of patients with heart failure and reduced ejection fraction, including angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, β-blockers, mineralocorticoid receptor antagonists, and the angiotensin 
receptor–neprilysin inhibitor, sacubitril/valsartan. Given that new trials build on evidence from previous trials, and the fact 
that new drugs have mainly been tested on top of existing ones, it becomes increasingly difficult for clinicians to maintain a 
perspective on the relative efficacy of the separate treatments and their combinations. This study systematically identified 57 
trials conducted over the past 34 years evaluating recommended treatment classes and combinations in patients with heart 
failure and reduced ejection fraction. Results from the systematic review were used to estimate the relative efficacy of these 
therapies with regards to survival, by means of network meta-analysis, providing insight into treatment comparisons in the 
absence of head-to-head trials. The network meta-analysis showed that all available treatment classes and combinations 
were more efficacious than placebo, with the exception of angiotensin II receptor blockers monotherapy and angiotensin 
II receptor blockers plus angiotensin-converting enzyme inhibitors. The combination of an angiotensin receptor–neprilysin 
inhibitor+β-blockers+mineralocorticoid receptor antagonists resulted in the greatest mortality reduction. Overall, these find-
ings help illustrate the step-wise reductions in mortality made possible by the incremental use of combinations of disease-
modifying therapies and validate the most recent global guideline recommendations.
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Expanded Methods & Results 
 
Search Strategy 
Databases:  Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R)) 
Date of search:  April 28, 2015 
1. exp Heart Failure/ 
2. Cardiomyopathy, Dilated/  
3. (heart failure or cardiac failure or cardiac insufficiency or cardiomyopath$).tw.  
4. ((cardi$ or myocard$) adj2 (failure$ or insufficien$)).tw. 
5. OR/1-4 
6. (LCZ696 or LCZ 696 or LCZ-696).af 
7. exp dipeptidyl carboxypeptidase inhibitor/ OR exp Angiotensin-Converting Enzyme 
Inhibitors/ 
8. (angiotensin converting enzyme inhibitor OR ACEI OR ACEI OR antagonist$ OR 
inhibitor$ benazepril OR captopril OR enalapril OR fosinopril OR imidapril OR lisinopril 
OR moexipril OR perindopril OR quinapril OR ramipril OR trandolapril OR zofenopril 
OR alacepril OR cilazapril OR spirapril OR delapril).mp. 
9. exp beta adrenergic receptor blocking agent/ OR exp Adrenergic beta-Antagonists/ 
10. (beta blocker$ OR BB OR acebutolol OR atenolol OR betaxolol OR bisoprolol OR 
carvedilol OR labetalol OR metoprolol OR nadolol OR nebivolol OR penbutolol OR 
pindolol OR propranolol OR sotalol OR timolol).mp. 
11. exp aldosterone antagonist/ 
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12. (aldosterone antagonist$ OR mineralocorticoid-receptor antagonist OR MRA OR 
eplerenone OR spironolactone).mp. 
13. exp angiotensin receptor antagonist/ 
14. (angiotensin receptor blocker$ OR angiotensin receptor antagonist$ OR ARB OR 
azilsartan OR candesartan OR eprosartan OR irbesartan OR losartan OR olmesartan OR 
telmisartan OR valsartan).mp. 
15. OR/6-14 
16. "randomized controlled trial".pt.  
17.  (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.  
18.  (retraction of publication or retracted publication).pt.  
19. OR/18-20 
20.  (animals not humans).sh.  
21.  ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal 
correspondence) not "randomized controlled trial").pt.  
22.  (random sampl$ or random digit$ or random effect$ or random survey or random 
regression).ti,ab. not "randomized controlled trial".pt.  
23. 20 OR 21 OR 22 
24. 19 NOT 23 
25. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.  
26. RETRACTED ARTICLE/ 
27. OR/25-26  
28. (animal$ not human$).sh,hw.  
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29. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled 
trial/  
30. (random sampl$ or random digit$ or random effect$ or random survey or random 
regression).ti,ab. not exp randomized controlled trial/  
31. OR/28-30 
32. 27 NOT 31 
33. 24 OR 32 
34. 5 AND 19 AND 33 
35. limit 34 to "all adult (19 plus years)" [Limit not valid in Embase; records were retained] 
36. limit 35 to (adult <18 to 64 years> or aged <65+ years>) [Limit not valid in Ovid 
MEDLINE(R),Ovid MEDLINE(R) In-Process; records were retained] 
37. limit 36 to human 
38. limit 37 to yr="1987 –July 2014" 
 
Database:   Cochrane Library of Clinical Trials 
Date of search: April 28, 2015 
#1  MeSH descriptor: [Heart Failure] explode all trees 
#2 MeSH descriptor: [Cardiomyopathy, Dilated] explode all trees 
#3 (heart failure or cardiac failure or cardiac insufficiency or cardiomyopath$):ti,ab,kw 
(Word variations have been searched)  
#4 #1 or #2 or #3 
#5 (LCZ696 or LCZ 696 or LCZ-696) :ti,ab,kw 
#6 MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees 
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#7 (angiotensin converting enzyme inhibitor or ACEI or ACEI or antagonist$ or inhibitor$ 
benazepril or captopril or enalapril or fosinopril or imidapril or lisinopril or moexipril or 
perindopril or quinapril or ramipril or trandolapril or zofenopril or alacepril or cilazapril 
or spirapril or delapril):ti,ab,kw (Word variations have been searched) 
#8 MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees 
#9 (beta blocker$ or BB or acebutolol or atenolol or betaxolol or bisoprolol or carvedilol or 
labetalol or metoprolol or nadolol or nebivolol or penbutolol or pindolol or propranolol or 
sotalol or timolol):ti,ab,kw (Word variations have been searched) 
#10 MeSH descriptor: [Mineralocorticoid Receptor Antagonists] explode all trees 
#11 (aldosterone antagonist$ or mineralocorticoid-receptor antagonist or MRA or eplerenone 
or spironolactone):ti,ab,kw (Word variations have been searched) 
#12 MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees 
#13 (angiotensin receptor blocker$ or angiotensin receptor antagonist$ or ARB or azilsartan 
or candesartan or eprosartan or irbesartan or losartan or olmesartan or telmisartan or 
valsartan):ti,ab,kw (Word variations have been searched) 
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13  
#15 #4 and #14 
#16 human not animal 
#17 #15 and #16 
#18 #17 in trials 




Supplementary Table 1: Drug classes of interest 
Class Generic name  Trade Name 
ARNI LCZ696 
valsartan/ sacubitril 
 Entresto  
ACEI benazepril   Lotensin 
 captopril  Capoten, Lopril 
 enalapril  Vasotec, Renitec 
 fosinopril  Monopril 
 imidapril  Tanatril 
 lisinopril  Prinivil, Zestril, Tensopril, Hipril, Lisodur, Novatec 
 moexipril  Univasc, Perdix 
 perindopril  Aceon, Coversyl  
 quinapril  Accupril 
 ramipril  Altace, Tritace, Ramace, Ramiwin, Prilace, Ramipro 
 trandolapril  Mavik 
 zofenopril  Bifril, Teoula, Zofepril, Zopranol 
 alacepril  Alacepul, Alaceril, Aprocorl, Asemipearl, Cenapride, Cetabavil, Cetapril, 
Cevozyl, Homerat, Iceden, Kananomin, Seplinok 
 cilazapril  Cazaprol, Cilan, Cilazabace, Cilazil, Dynorm, Dynorm Plus, Inhibace Plus, 
Inhibace, Initiss, Inocar, Justor, Prilazid, Vascace, Zobox, Cilazapril-Teva, 
CO Cilazapril, Gen-Cilazapril, Inhirock, Inibace Plus, Initiss Plus, Inocar 
Plus 
 spirapril  Quadropril, Renormax, Renpress, Setrilan 
 delapril  Beniod, Delaket, Delapride, Dinapres, Trinordiol, Adecut, Araplit, 
Cupressin, Defolder, Virace 
BB acebutolol  Sectral, Prent 
 atenolol  Tenormin, Senormin 
 betaxolol  Kerlone, Betoptic, Lokren 
 bisoprolol  Zebeta 
 carvedilol  Coreg, Carvil, Dilatrend, Eucardic, Carloc 
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Class Generic name  Trade Name 
 labetalol  Trandate, Normodyne 
 metoprolol  Lopressor, Toprol, Selokeen, Minax, Metrol, Betaloc, Bloxan, Neobloc, 
Presolol, Corvitol, Metxl, Metolar, Starpress 
 nadolol  Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol 
 nebivolol  Bystolic, Nebilet, Nebilong, Nebicard, Nubeta, Nodon, Lobivon 
 penbutolol  Levatol, Levatolol, Lobeta, Paginol, Hostabloc, Betapressin 
 pindolol  Visken, Betapindol, Blockin L, Calvisken, Cardilate, Decreten, Durapindol, 
Glauco-Visken, Pectobloc, Pinbetol, Prindolol, Pynastin 
 propranolol  Inderal, InnoPran, Avlocardyl, Deralin, Dociton, Inderalici, Sumial, 
Anaprilinum, Bedranol  
 sotalol  Betapace, Sotalex, Sotacor  
 timolol  Blocadren, Timoptic 
MRA eplerenone  Inspra 
 spironolactone  Aldactone, Novo-Spiroton, Aldactazide, Spiractin, Spirotone,  
Verospiron, Berlactone 
ARB azilsartan  Edarbi 
 candesartan  Atacand, Blopress, Amias, Ratacand 
 eprosartan  Teveten, Eprozar 
 irbesartan  Avapro, Karvea, Aprovel 
 losartan  Cozaar 
 olmesartan  Benicar, Olmetec 
 telmisartan  Micardis, Targit, Temax, Telmore 
 valsartan  Diovan, Angiotan, Valtan, Valzaar, Tareg 
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin-II receptor antagonist; ARNI = 
angiotensin receptor-neprilysin inhibitor; BB = beta blocker; MRA = mineralocorticoid receptor antagonist; NR = not 




Supplementary Table 2: Study design and baseline patient characteristics of included RCTs 



















































































































































































































































































≤40% 28% 85% 54 0% 61% 39% 0% 40 NR NR 











≤40% 30% 67% 73 0% 65% 34% 2% NR 68% 50% 
















































≤45% 25% 78% 58 0% 47% 51% 2% 53 47% 
NR 
















































































































≤35% 23% 78% 60 0% 0% 92% 8% 37 42% NR 









< 40% 17% 83% 60 0% 0% 95% 5% 38 54% 47% 














































































































































































































































































































≤30% 26% 78% 69 0% 100% 0% 0% 58 69% 50% 




































≤40% 29% 78% 64 5% 70% 24% 1% NR 60% 43% 
Abbreviations: AUS = Australia; d = day(s); DB = double-blind; EU = Europe; heart failure = heart failure; MC = multicentre; mos = months; MI = myocardial infarction; NA = North America; NYHA 
= New York heart association; LVEF = left ventricular ejection fraction; mo = month(s); NR = not reported; OL = open label; PC = placebo controlled; SB = single blind; SC = single centre; US = 








Main Intervention ACEI % ARB % BB %  MRA % Digoxin % Diuretics % 
CASSIS 1995 ACEI Spirapril 5% NR NR NR 91% 96% 
CASSIS 1995 ACEI Spirapril 5% NR NR NR 91% 96% 
CASSIS 1995 ACEI Spirapril 5% NR NR NR 91% 96% 
CASSIS 1995 ACEI Enalapril 5% NR NR NR 91% 96% 
CASSIS 1995 PLBO Placebo 5% NR NR NR 91% 96% 
CONSENSUS 1987 ACEI Enalapril not allowed NR 4% NR 92% 100% 
CONSENSUS 1987 PLBO Placebo not allowed NR 2% NR 94% 100% 
FEST 1995 ACEI Fosinopril NR NR NR NR 61% 100% 
FEST 1995 PLBO Placebo NR NR NR NR 62% 100% 
MHFT 1991 ACEI Captopril NR NR 23% NR 59% 79% 
MHFT 1991 PLBO Placebo NR NR 23% NR 59% 79% 
SOLVD-prevent 1992 ACEI Enalapril not allowed NR NR NR 12% 16% 
SOLVD-prevent 1992 PLBO Placebo not allowed NR NR NR 13% 17% 
SOLVD-treat 1991 ACEI Enalapril not allowed NR 8% NR 66% 86% 
SOLVD-treat 1991 PLBO Placebo not allowed NR 7% NR 68% 85% 
Beller 1995 ACEI Lisinopril NR NR NR NR 94% 99% 
Beller 1995 PLBO Placebo NR NR NR NR 86% 97% 
Brown 1995 ACEI Fosinopril not allowed NR not allowed NR 53% 100% 
Brown 1995 PLBO Placebo not allowed NR not allowed NR 54% 100% 
Chalmers 1987 ACEI Lisinopril NR NR NR 10% 60% 55% 
Chalmers 1987 PLBO Placebo NR NR NR 14% 72% 49% 
Colfer 1992 ACEI Benazepril NR NR not allowed NR 100% 100% 
Colfer 1992 PLBO Placebo NR NR not allowed NR 100% 100% 
Goldstein 1988 ACEI Captopril NR NR NR NR 60% NR 
Goldstein 1988 PLBO Placebo NR NR NR NR 67% NR 
Lewis 1989 ACEI Lisinopril NR NR NR NR 100% 100% 
Lewis 1989 PLBO Placebo NR NR NR NR 100% 100% 
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Shettigar 1999 ACEI Fosinopril not allowed NR not allowed NR 42% 100% 
Shettigar 1999 PLBO Placebo not allowed NR not allowed NR 47%% 100% 
Veldhuisen 1999 ACEI Imidapril NR NR not allowed NR 23% 34% 
Veldhuisen 1999 ACEI Imidapril NR NR not allowed NR 26% 25% 
Veldhuisen 1999 ACEI Imidapril NR NR not allowed NR 24% 30% 
Veldhuisen 1999 PLBO Placebo NR NR not allowed NR 19% 25% 
SPICE 2000 ARB Candesartan not allowed not allowed 22% NR 60% NR 
SPICE 2000 PLBO Placebo not allowed not allowed 20% NR 63% NR 
STRETCH 1999 ARB Candesartan not allowed NR 1% NR 40% 61% 
STRETCH 1999 ARB Candesartan not allowed NR 1% NR 43% 63% 
STRETCH 1999 ARB Candesartan not allowed NR 0% NR 42% 58% 
STRETCH 1999 PLBO Placebo not allowed NR 1% NR 39% 58% 
Mitrovic 2003 ARB Candesartan not allowed not allowed NR NR 78% NR 
Mitrovic 2003 ARB Candesartan not allowed not allowed NR NR 65% NR 
Mitrovic 2003 ARB Candesartan not allowed not allowed NR NR 80% NR 
Mitrovic 2003 ARB Candesartan not allowed not allowed NR NR 77% NR 
Mitrovic 2003 PLBO Placebo not allowed not allowed NR NR 82% NR 
ELITE I 1997 ARB Losartan not allowed not allowed 16% NR 57% 74% 
ELITE I 1997 ACEI Captopril not allowed not allowed 17% NR 56% 74% 
ELITE II 2000 ARB Losartan not allowed not allowed 23% NR 50% 77% 
ELITE II 2000 ACEI Captopril not allowed not allowed 21% NR 50% 79% 
REPLACE 2001 ACEI Enalapril not allowed not allowed NR NR 39% NR 
REPLACE 2001 ARB Telmisartan not allowed not allowed NR NR 39% NR 
REPLACE 2001 ARB Telmisartan not allowed not allowed NR NR 39% NR 
REPLACE 2001 ARB Telmisartan not allowed not allowed NR NR 39% NR 
REPLACE 2001 ARB Telmisartan not allowed not allowed NR NR 39% NR 
Dickstein 1995 ARB Losartan NR NR 19% NR 58% NR 
Dickstein 1995 ARB Losartan NR NR 11% NR 73% NR 
Dickstein 1995 ACEI Enalapril NR NR 7% NR 59% NR 
Lang 1997 ARB Losartan not allowed NR 11% NR 82% 100% 
Lang 1997 ARB Losartan not allowed NR 3% NR 85% 100% 
Lang 1997 ACEI Enalapril not allowed NR 8% NR 87% 97% 
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CIBIS III 2008 BB Bisoprolol then Enalapril not allowed NR not allowed 14% 33% NR 
CIBIS III 2008 ACEI Enalapril then Bisoprolol not allowed NR not allowed 12% 31% NR 
CARMEN 2004 BB Carvedilol + placebo not allowed NR not allowed 15% 44% 67% 
CARMEN 2004 ACEI Enalapril + placebo not allowed NR not allowed 13% 44% 74% 
CARMEN 2004 ACEI + BB Carvedilol + enalapril not allowed NR not allowed 12% 47% 73% 
RALES 1999 ACEI + MRA Spironolactone 95% NR 11% not allowed 75% 95% 
RALES 1999 ACEI Placebo 94% NR 10% not allowed 72% 94% 
Val-HeFT 2001 ACEI + ARB Valsartan 93% not allowed 35% NR 67% NR 
Val-HeFT 2001 ACEI  Placebo 93% not allowed 35% NR 68% NR 
Hamroff 1999 ACEI + ARB Losartan 100% NR 6% NR 100% 100% 
Hamroff 1999 ACEI Placebo 100% NR 6% NR 94% 100% 
BEST 2001 ACEI + BB Bucindolol 91% 6% not allowed 3% 93% NR 
BEST 2001 ACEI  Placebo 91% 7% not allowed 4% 92% NR 
CELICARD 2000 ACEI + BB Celiprolol 80% NR not allowed NR 51% NR 
CELICARD 2000 ACEI Placebo 90% NR not allowed NR 66% NR 
CIBIS I 1994 ACEI + BB Bisoprolol 89% NR NR NR 57% 100% 
CIBIS I 1994 ACEI Placebo 91% NR NR NR 56% 100% 
CIBIS II 1999 ACEI + BB Bisoprolol 96% NR NR NR 53% 98% 
CIBIS II 1999 ACEI Placebo 96% NR NR NR 51% 99% 
COPERNICUS 2001 ACEI + BB Carvedilol 97%* 97%* not allowed 19% 67% NR 
COPERNICUS 2001 ACEI Placebo 97%* 97%* not allowed 20% 65% NR 
ENECA 2005 ACEI + BB Nebivolol 91% 5% not allowed NR 60% NR 
ENECA 2005 ACEI Placebo 92% 7% not allowed NR 53% NR 
MERIT-heart failure 1999 ACEI + BB Metoprolol 89% 7% not allowed 7% 63% 91% 
MERIT-heart failure 1999 ACEI Placebo 90% 6% not allowed 8% 64% 90% 
MERIT-heart failure (pilot) 
1999 
ACEI + BB Metoprolol 95% NR NR NR 91% NR 
MERIT-heart failure (pilot) 
1999 
ACEI Placebo 89% NR NR NR 90% NR 
MIC 2000 ACEI + BB Metoprolol 92% NR not allowed NR 51% NR 
MIC 2000 ACEI Placebo 91% NR not allowed NR 52% NR 
MOCHA 1996 ACEI + BB Carvedilol (low-dose) 93% NR not allowed NR 99% 98% 
MOCHA 1996 ACEI + BB Carvedilol (medium-dose) 99% NR not allowed NR 88% 96% 
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MOCHA 1996 ACEI + BB Carvedilol (high-dose) 89% NR not allowed NR 90% 93% 
MOCHA 1996 ACEI Placebo 94% NR not allowed NR 93% 93% 
PRECISE 1996 ACEI + BB Carvedilol 96% NR not allowed NR 91% 98% 
PRECISE 1996 ACEI Placebo 97% NR not allowed NR 88% 99% 
SYMPOXYDEX 2004 ACEI + BB Carvedilol 96% NR not allowed NR NR 100% 
SYMPOXYDEX 2004 ACEI Placebo 96% NR not allowed NR NR 100% 
Cohn 1997 ACEI + BB Carvedilol 94% NR NR NR 90% 97% 
Cohn 1997 ACEI Placebo 91% NR NR NR 89% 100% 
Colucci 1996 ACEI + BB Carvedilol 98% NR not allowed NR 89% NR 
Colucci 1996 ACEI Placebo 98% NR not allowed NR 89% NR 
de Milliano 2002 ACEI + BB Metoprolol 93% NR not allowed NR 28% NR 
de Milliano 2002 ACEI Placebo 91% NR not allowed NR 36% NR 
Dubach 2002 ACEI + BB Bisoprolol 100% NR not allowed NR 5% NR 
Dubach 2002 ACEI Placebo 100% NR not allowed NR 9% NR 
Krum 1995 ACEI + BB Carvedilol 90% NR NR NR NR NR 
Krum 1995 ACEI Placebo 90% NR NR NR NR NR 
Packer 1996 ACEI + BB Carvedilol 95% NR not allowed NR 91% 95% 
Packer 1996 ACEI Placebo 95% NR not allowed NR 90% 95% 
Palazzuoli 2005 ACEI + BB Carvedilol 100% NR not allowed NR NR NR 
Palazzuoli 2005 ACEI Placebo 100% NR not allowed NR NR NR 
Palazzuoli 2005 ACEI + BB Carvedilol 100% NR not allowed NR NR NR 
Palazzuoli 2005 ACEI Placebo 100% NR not allowed NR NR NR 
Sturm 2000 ACEI + BB Atenolol + enalapril 100% NR not allowed NR 51% NR 
Sturm 2000 ACEI Placebo + enalapril 100% NR not allowed NR 49% NR 
HEAVEN 2002 ARB + BB Valsartan not allowed not allowed 52% NR 26% NR 
HEAVEN 2002 ACEI + BB Enalapril not allowed not allowed 56% NR 32% NR 
CHARM-alternative 2003 ARB + BB Candesartan not allowed not allowed 55% 25% 60% NR 
CHARM-alternative 2003 BB Placebo not allowed not allowed 55% 23% 63% NR 
RESOLVD 2000 ACEI + ARB + BB (Candesartan, enalapril, or 






not allowed NR 65% NR 
ACEI + 
ARB: 41% 
RESOLVD 2000 ACEI + ARB (Candesartan, enalapril, or 










RESOLVD 2003 ARB + BB (Candesartan or enalapril) + 
metoprolol 
23% 77% not allowed NR 68% 82% 
RESOLVD 2003 ACEI + ARB + BB (Candesartan + enalapril) + 
metoprolol 
not allowed not allowed  not allowed NR 62% 83% 
RESOLVD 2003 ARB (Candesartan or enalapril) + placebo 33% 67% not allowed NR 74% 85% 
RESOLVD 2003 ACEI + ARB (Candesartan + enalapril) + placebo not allowed not allowed not allowed NR 70% 83% 
CHARM-added 2003 ACEI + ARB + BB Candesartan 100% not allowed 55% 17% 58% NR 
CHARM-added 2003 ACEI + BB Placebo 100% not allowed 56% 17% 59% NR 
AREA-IN CHF 2009 ACEI + BB + MRA Canrenone 85% 12% 81% not allowed 24% NR 
AREA-IN CHF 2009 ACEI + BB Placebo 75% 24% 78% not allowed 27% NR 
EMPHASIS-heart failure 
2011 
ACEI + BB + MRA Eplerenone 78% 19% 87% not allowed 27% 84% 
EMPHASIS-heart failure 
2011 
ACEI + BB Placebo 77% 19% 87% not allowed 28% 86% 
Cicoira 2002 ACEI + BB + MRA Spironolactone 100% NR 72% not allowed NR NR 
Cicoira 2002 ACEI + BB Placebo 100% NR 65% not allowed NR NR 
Vizzardi 2014 ACEI + BB + MRA Spironolactone 100%* 100%* 97% NR NR 75% 
Vizzardi 2014 ACEI + BB Placebo 100%* 100%* 98% NR NR 86% 
PARADIGM-heart failure 
2014 
ARNI + BB + MRA Sacubitril/valsartan not allowed NR 93% 54% 29% 80% 
PARADIGM-heart failure 
2014 
ACEI + BB + MRA Enalapril not allowed NR 93% 57% 31% 80% 
* data presented for ACEI/ARB 
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin-II receptor antagonist; ARNI = angiotensin receptor-neprilysin inhibitor; BB = beta blocker; MRA = 








Supplementary Table 4: Proportion of patients taking concomitant ACEI and ARB in 
RCTs that allow concomitant use of ACEI or ARB  





ACEI or ARB allowed 9 100% 
≥90% patients taking ACEI 3/9 33% 
≥75% patients taking ACEI 6/9 67% 
Only present pooled % (ACEI or ARB) 2/9 22% 
Treatment classification unclear* 1/9 11% 
* RESOLVD trial 51,52 




















ACEI Colfer 1992 Benazepril 20mg OD 20mg 12 weeks (titration first 8 weeks) 
ACEI MHFT 1991 Captopril 25mg BID 40mg Median: 2.7 years 
ACEI ELITE I 1997 Captopril 50mg TID 150mg 48 weeks (uptitration every 7 days) 
ACEI ELITE II 2000 Captopril 50mg TID 150mg 700 days 
ACEI Anonymous 1988 Captopril 50mg TID 150mg 24 weeks (uptitrated from 25mg/day if 
tolerated) 
ACEI Dickstein 1995 Enalapril 10mg BID 20mg 8 weeks 
ACEI REPLACE 2001 Enalapril 10mg BID 20mg 12 weeks 
ACEI CARMEN 2004 Enalapril 10mg BID 20mg 18 months (plus upward titration and 
downward titration, undefined lengths 
of time 
ACEI CASSIS 1995 Enalapril 10mg OD 10mg 12 weeks 
ACEI SOLVD-treat 1991 Enalapril 10mg BID 20mg 48 months 
ACEI SOLVD-prevent 1992 Enalapril 10mg BID 20mg 37.4 months (mean) 
ACEI CIBIS III 2008 Enalapril 10mg BID 20mg/10mg 6 months 
ACEI CONSENSUS 1987 Enalapril 10mg-20mg BID 20mg-40mg 52 weeks 
ACEI  Lang 1997 Enalapril 20mg BID 40mg 12 weeks 
ACEI  Sturm 2000 Enalapril 40mg OD 40mg 2 years (includes titration) 
ACEI Brown 1995 Fosinopril 20mg OD 20mg 24 weeks 
ACEI FEST 1995 Fosinopril 40mg OD 40mg 12 weeks 
ACEI Shettigar 1999 Fosinopril 40mg OD 40mg 12 weeks (uptitration over first 4-
weeks) 
ACEI Veldhuisen 1999* Imidapril 2.5mg OD 2.5mg 12 weeks 
ACEI Veldhuisen 1999* Imidapril 5mg OD 5mg 12 weeks 
ACEI Veldhuisen 1999 Imidapril 10mg OD 10mg 12 weeks 
ACEI Beller 1995 Lisinopril 5mg-20mg OD 5mg-20mg 12 weeks 
ACEI Chalmers 1987 Lisinopril 5mg-20mg OD 5mg-20mg 12 weeks 
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ACEI Lewis 1989 Lisinopril 5-20mg OD 5-20mg 12 weeks 
ACEI CASSIS 1995* Spirapril 1.5mg OD 1.5mg 12 weeks 
ACEI CASSIS 1995* Spirapril 3mg OD 3mg 12 weeks 
ACEI CASSIS 1995 Spirapril 6mg OD 6mg 12 weeks 
ACEI MERIT-heart failure 1999 Placebo NA NA NA 18 months (including 6-8 week 
titration) 
ACEI MOCHA 1996 Placebo NA NA NA 6 months (plus 2-4 week titration) 
ACEI SYMPOXYDEX 2004 Placebo NA NA NA 6 months (including 6 weeks titration) 
ACEI Cohn 1997 Placebo NA NA NA 6 months (plus 4 week titration) 
ACEI Val-HeFT 2001 Placebo NA NA NA 38 months (including 4 weeks titration) 
ACEI de Milliano 2002 Placebo NA NA NA 6 months (plus 10 wks titration) 
ACEI Dubach 2002 Placebo NA NA NA 12 months (titration first month) 
ACEI ENECA 2005 Placebo NA NA NA 48 weeks (includes 6 week titration 
period) 
ACEI BEST 2001 Placebo NA NA NA 42 months (titration first 6 weeks) 
ACEI MIC 2000 Placebo NA NA NA 6 months (including 6 week titration) 
ACEI MERIT-heart failure (pilot) 
1999 
Placebo NA NA NA 26 weeks (titration first 8 weeks) 
ACEI Hamroff 1999 Placebo NA NA NA 6 months 
ACEI CIBIS I 1994 Placebo NA NA NA 2 years (mean duration 1.9) 
ACEI CIBIS II 1999 Placebo NA NA NA mean duration: 1.3 years (titration 
weeks 1-5) 
ACEI PRECISE 1996 Placebo NA NA NA 6 months 
ACEI Packer 1996 Placebo NA NA NA 6 months (plus 2-10 week titration 
(mild heart failure protocol;12 months 
+ titration) 
ACEI Colucci 1996 Placebo NA NA NA 52 weeks (plus uptitration 2-6 weeks) 
ACEI Krum 1995 Placebo NA NA NA 14 weeks (titration in first week) 
ACEI COPERNICUS 2001 Placebo NA NA NA 28.7 months (includes approximately 8 
week titration period) 
ACEI Palazzuoli 2005 Placebo NA NA NA 12 months (titration first 7 weeks) 
ACEI Palazzuoli 2005 Placebo NA NA NA 12 months (titration first 7 weeks) 
ACEI RALES 1999 Placebo NA NA NA 24 months 
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ACEI CELICARD 2000 Placebo NA NA NA 1 year (including 1 month titration 
period) 
BB CIBIS III 2008 Bisoprolol 10mg OD 10mg 26 weeks (including 10 week titration) 
BB CARMEN 2004 Carvedilol 25mg or 
50mg if 
>85kg 
BID 50mg or 
100mg if 
>85kg 
18 months (plus upward titration and 
downward titration, undefined lengths 
of time 
BB CHARM-alternative 2003 Placebo NA NA NA 33.7 months (median follow-up, plus 6 
weeks titration period) 
ARB SPICE 2000 Candesartan 16mg OD 16mg 12 weeks (including 4 weeks titration) 
ARB STRETCH1999* Candesartan 4mg OD 4mg 12 weeks 
ARB STRETCH1999* Candesartan 8mg OD 8mg 12 weeks 
ARB STRETCH1999 Candesartan 16mg OD 16mg 12 weeks 
ARB Lang 1997 Losartan* 25mg OD 25mg 12 weeks 
ARB Lang 1997 Losartan 50mg OD 50mg 12 weeks 
ARB Mitrovic 2003* Candesartan 2mg OD 2mg 12 weeks (titration first 3 weeks) 
ARB Mitrovic 2003* Candesartan 4mg OD 4mg 12 weeks (titration first 3 weeks) 
ARB Mitrovic 2003* Candesartan 8mg OD 8mg 12 weeks (titration first 3 weeks) 
ARB Mitrovic 2003 Candesartan 16mg OD 16mg 12 weeks (titration first 3 weeks) 
ARB Dickstein 1995* Losartan 25mg OD 25mg 8 weeks 
ARB Dickstein 1995 Losartan 50mg OD 50mg 8 weeks 
ARB ELITE I 1997 Losartan 50mg OD 50mg 48 weeks (uptitration every 7 days) 
ARB ELITE II 2000 Losartan 50mg OD 50mg 700 days 
ARB REPLACE 2001* Telmisartan 10mg OD 10mg 12 weeks 
ARB REPLACE 2001* Telmisartan 20mg OD 20mg 12 weeks 
ARB REPLACE 2001* Telmisartan 40mg OD 40mg 12 weeks 
ARB REPLACE 2001 Telmisartan 80mg OD 80mg 12 weeks 
ACEI + 
ARB 
RESOLVD 2003 (Candesartan + 
enalapril) + 
placebo 
NA NA NA 19 weeks without placebo  (including 
mean titration 93 days), placebo 
received for 24weeks (43 weeks total) 
ACEI + 
ARB 
Hamroff 1999 Losartan 50mg OD 50mg 6 months 
ACEI + 
ARB 
Val-HeFT 2001 Valsartan 160mg BID 320mg 38 months (including 4 weeks titration) 
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2 years (includes titration) 
ACEI + BB Dubach 2002 Bisoprolol 10mg daily 10mg 12 months (titration first month) 
ACEI + BB CIBIS I 1994 Bisoprolol 5mg OD 5mg 2 years (mean duration 1.9) 
ACEI + BB CIBIS II 1999 Bisoprolol 2.5-10mg OD 2.5-10mg mean duration: 1.3 years (titration 
weeks 1-5) 




BID 100mg or 
200mg 
42 months (titration first 6 weeks) 
ACEI + BB SYMPOXYDEX 2004 Carvedilol 25mg BID 50mg 6 months (including 6 weeks titration) 
ACEI + BB Cohn 1997 Carvedilol 25mg BID 50mg 6 months (plus 4 week titration) 
ACEI + BB PRECISE 1996 Carvedilol 25mg BID 50mg 6 months 
       
ACEI + BB Krum 1995 Carvedilol 25mg BID 50mg 14 weeks (titration in first week) 
ACEI + BB Packer 1996 Carvedilol 25-50mg BID 50mg-
100mg 
6 months (plus 2-10 week titration 
(mild heart failure protocol;12 months 
+ titration) 
ACEI + BB Colucci 1996 Carvedilol 25-50mg BID 50-100mg 52 weeks (plus uptitration 2-6 weeks) 
ACEI + BB COPERNICUS 2001 Carvedilol 25mg BID 50mg 28.7 months (includes approximately 8 
week titration period) 
ACEI + BB Palazzuoli 2005 Carvedilol 50mg daily 50mg 12 months (titration first 7 weeks) 
ACEI + BB Palazzuoli 2005 Carvedilol 50mg daily 50mg 12 months (titration first 7 weeks) 
ACEI + BB MOCHA 1996* Carvedilol (low-
dose) 
6.25mg BID 12.5mg 6 months (plus 2-4 week titration) 
ACEI + BB MOCHA 1996* Carvedilol 
(medium-dose) 
12.5mg BID 25mg 6 months (plus 2-4 week titration) 
ACEI + BB MOCHA 1996 Carvedilol (high-
dose) 
25mg BID 50mg 6 months (plus 2-4 week titration) 





BID 50mg or 
100mg if 
>85kg/20mg 
18 months (plus upward titration and 
downward titration, undefined lengths 
of time 




ACEI + BB MERIT-heart failure 1999 Metoprolol 200mg daily 200mg 18 months (including 6-8 week 
titration) 
ACEI + BB MERIT-heart failure (pilot) 
1999 
Metoprolol 150mg o.d. 150 mg 26 weeks (titration first 8 weeks) 
ACEI + BB de Milliano 2002 Metoprolol 50, 100 or 
150mg 
daily 50, 100 or 
150mg 
6 months (plus 10 wks titration) 
ACEI + BB MIC 2000 Metoprolol NR NR 135mg 
(mean) 
6 months (including 6 week titration) 
ACEI + BB ENECA 2005 Nebivolol 10mg daily 10mg 48 weeks (includes 6 week titration 
period) 
ACEI + BB HEAVEN 2002 Enalapril 10mg BID 20mg 12 weeks (including titration) 
ACEI + BB AREA-IN CHF 2009 Placebo NA NA NA 12 months 
ACEI + BB Cicoira 2002 Placebo NA NA NA 12 months (includes titration) 
ACEI + BB Vizzardi 2014 Placebo 25mg OD 25mg 44 months (mean) 
ACEI + BB CHARM-added 2003 Placebo NA NA NA 41 months (median follow-up, plus 6 
weeks titration period) 
ACEI + BB EMPHASIS-heart failure 2011 Placebo NA NA NA 3 years 
ARB + BB HEAVEN 2002 Valsartan 160mg OD 160mg 12 weeks (including titration) 
ARB + BB CHARM-alternative 2003 Candesartan 32mg OD 32mg 33.7 months (median follow-up, plus 6 
weeks titration period) 
ACEI + 
MRA 





ARB + BB 
RESOLVD 2003 (Candesartan + 
enalapril) + 
metoprolol 
200mg daily 200mg 19 weeks without metoprolol  
(including mean titration 93 days), 
metoprolol received for 24weeks (43 
weeks total) 
ACEI + 
ARB + BB 
CHARM-added 2003 Candesartan 32mg OD 32mg 41 months (median follow-up, plus 6 
weeks titration period) 
ACEI + BB 
+ MRA 
AREA-IN CHF 2009 Canrenone 50mg OD 50mg 12 months 
ACEI + BB 
+ MRA 
EMPHASIS-heart failure 2011 Eplerenone 50mg OD 50mg 3 years 
ACEI + BB 
+ MRA 
PARADIGM-heart failure 2014 Enalapril 10mg BID 20mg 27 months (median) 
ACEI + BB 
+ MRA 
Cicoira 2002 Spironolactone 50mg OD 50mg 12 months (includes titration) 
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ACEI + BB 
+ MRA 
Vizzardi 2014 Spironolactone 25mg-100mg OD-QID 25mg-
400mg 
44 months (mean) 
ARNI + BB 
+ MRA 
PARADIGM-heart failure 2014 Sacubitril/valsarta
n 
200mg BID 400mg 27 months (median) 
PLBO Beller 1995 Placebo 5mg-20mg OD 5mg-20mg 12 weeks 
PLBO Brown 1995 Placebo NA NA NA 24 weeks 
PLBO Chalmers 1987 Placebo 5mg-20mg OD 5mg-20mg 12 weeks 
PLBO STRETCH 1999 Placebo NA NA NA 12 weeks 
PLBO Anonymous 1988 Placebo NA NA NA 24 weeks (uptitrated from 25mg/day if 
tolerated) 
PLBO Colfer 1992 Placebo NA NA NA 12 weeks (titration first 8 weeks) 
PLBO FEST 1995 Placebo NA NA NA 12 weeks 
PLBO SPICE 2000 Placebo NA NA NA 12 weeks (including 4 weeks titration) 
PLBO MHFT 1991 Placebo NA NA NA Median: 2.7 years 
PLBO Lewis 1989 Placebo NA NA NA 12 weeks 
PLBO Mitrovic 2003 Placebo NA NA NA 12 weeks (titration first 3 weeks) 
PLBO Shettigar 1999 Placebo NA NA NA 12 weeks (uptitration over first 4-
weeks) 
PLBO CONSENSUS 1987 Placebo NA NA NA 52 weeks 
PLBO Veldhuisen 1999 Placebo NA NA NA 12 weeks 
PLBO CASSIS 1995 Placebo NA NA NA 12 weeks 
PLBO SOLVD-treat 1991 Placebo NA NA NA 48 months 
PLBO SOLVD-prevent 1992 Placebo NA NA NA 37.4 months (mean) 
* Arm excluded from analysis (more common dose available) 
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin-II receptor antagonist; ARNI = angiotensin receptor-neprilysin inhibitor; 
BB = beta blocker; BID = twice daily; mg = milligrams; MRA = mineralocorticoid receptor antagonist; NA = not applicable; NR = not reported; OD = once 
daily; PLBO = placebo; QID = four times daily; TID = three times daily
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Supplementary Figure 2: Rates per patient year sorted by publication year and presented by treatment arm for A) Placebo, B) 

























PLBO CONSENSUS 1987 12.0 126 108 117 66 0.56 0.72 0.44
PLBO Chalmers 1987 3.0 43 35 10 3 0.31 0.90 0.06
min PLBO Goldstein 1988 6.0 100 100 50 6 0.12 0.26 0.04
PLBO Lew is 1989 3.0 43 43 11 3 0.28 0.82 0.06
PLBO SOLVD treat 1991 55.0 1284 752 4667 510 0.11 0.12 0.10
PLBO Colfer 1992 3.0 58 45 13 3 0.23 0.68 0.05
PLBO MHFT 1992 36.5 87 74 245 22 0.09 0.14 0.06
PLBO SOLVD prevent 1992 48.0 2117 1164 6563 334 0.05 0.06 0.05
PLBO CASSIS 1995 3.0 48 42 11 6 0.53 1.16 0.19
PLBO Beller 1995 3.0 63 46 14 5 0.37 0.85 0.12
PLBO FEST 1995 3.0 153 118 34 3 0.09 0.26 0.02
PLBO Brow n 1995 6.0 125 74 50 4 0.08 0.21 0.02
PLBO RALES (dosing) 1996 3.0 40 40 10 0 0.00 0.00 0.00
PLBO Veldhuisen 1998 3.0 62 54 15 1 0.07 0.38 0.00
PLBO Shettigar 1999 3.0 104 60 21 3 0.15 0.43 0.03
PLBO STRETCH 1999 3.0 211 211 53 1 0.02 0.11 0.00
PLBO SPICE 2000 3.0 91 79 21 3 0.14 0.41 0.03
PLBO Mitrovic 2003 3.0 44 34 10 2 0.21 0.74 0.02
PLBO CHARM-alt 2003 42.0 1015 1015 3553 296 0.08 0.09 0.07























ACEI CONSENSUS 1987 12.0 127 105 116 46 0.40 0.53 0.29
ACEI Chalmers 1987 3.0 87 72 20 4 0.20 0.52 0.05
min ACEI Goldstein 1988 6.0 104 104 52 8 0.15 0.30 0.07
ACEI Lew is 1989 3.0 87 87 22 4 0.18 0.47 0.05
ACEI SOLVD treat 1991 55.0 1285 867 4933 452 0.09 0.10 0.08
ACEI MHFT 1992 40.4 83 59 239 22 0.09 0.14 0.06
ACEI SOLVD prevent 1992 48.0 2111 1942 8106 313 0.04 0.04 0.03
ACEI Colfer 1992 3.0 114 98 27 0 0.00 0.00 0.00
ACEI CIBIS I 1994 26.0 321 239 607 67 0.11 0.14 0.09
ACEI CASSIS 1995 3.0 51 47 12 3 0.24 0.72 0.05
ACEI Dickstein 1995 2.0 58 58 10 2 0.21 0.75 0.02
ACEI CASSIS 1995 3.0 48 42 11 2 0.18 0.64 0.02
ACEI FEST 1995 3.0 155 127 35 5 0.14 0.33 0.05
ACEI Beller 1995 3.0 130 105 29 4 0.14 0.35 0.04
ACEI Brow n 1995 6.0 116 81 49 3 0.06 0.18 0.01
ACEI Krum 1995 3.5 16 14 4 2 0.46 1.65 0.05
ACEI MOCHA 1996 6.0 84 63 37 13 0.35 0.60 0.19
ACEI Packer 1996 6.0 398 398 199 31 0.16 0.22 0.11
ACEI PRECISE 1996 6.0 145 145 73 11 0.15 0.27 0.08
ACEI Colucci 1996 12.0 134 134 134 5 0.04 0.09 0.01
ACEI Cohn 1997 6.0 35 27 16 2 0.13 0.47 0.01
ACEI ELITE I 1997 11.0 370 259 288 32 0.11 0.16 0.08
ACEI Lang 1997 3.0 38 38 10 0 0.00 0.00 0.00
ACEI Veldhuisen 1998 3.0 60 56 15 0 0.00 0.00 0.00
ACEI RALES 1999 24.0 841 630 1471 386 0.26 0.29 0.24
ACEI Hamroff 1999 6.0 17 13 8 1 0.13 0.70 0.00
ACEI MERIT-HF 1999 12.0 2001 1691 1846 217 0.12 0.13 0.10
ACEI Shettigar 1999 3.0 102 85 23 2 0.09 0.31 0.01
ACEI CIBIS II 1999 46.0 1320 1320 5063 228 0.05 0.05 0.04
ACEI Goldstein 1999 6.0 19 16 9 0 0.00 0.00 0.00
ACEI MIC 2000 6.0 26 19 11 2 0.18 0.64 0.02
ACEI Sturm 2000 24.0 49 20 69 8 0.12 0.23 0.05
ACEI ELITE II 2000 24.0 1574 1353 2927 250 0.09 0.10 0.08
ACEI CELICARD 2000 12.0 66 39 53 4 0.08 0.20 0.02
ACEI REPLACE 2001 3.0 75 75 19 2 0.11 0.39 0.01
ACEI COPERNICUS 2001 21.0 1133 953 1825 190 0.10 0.12 0.09
ACEI BEST 2001 42.0 1354 1351 4734 449 0.09 0.10 0.09
ACEI Val-HeFT 2001 27.0 2499 2499 5623 484 0.09 0.09 0.08
ACEI HEAVEN 2002 3.0 71 62 17 5 0.30 0.70 0.10
ACEI de Milliano 2002 6.0 11 10 5 1 0.19 1.06 0.00
ACEI Dubach 2002 12.0 15 15 15 0 0.00 0.00 0.00
ACEI SYMPOXYDEX 2004 6.0 22 21 11 1 0.09 0.52 0.00
ACEI CARMEN 2004 18.0 190 133 242 14 0.06 0.10 0.03
ACEI Palazzuoli 2005b 12.0 27 24 26 2 0.08 0.28 0.01
ACEI ENECA 2005 11.0 126 112 119 7 0.06 0.12 0.02
ACEI Palazzuoli 2005 12.0 25 22 24 1 0.04 0.24 0.00
ACEI CIBIS III 2008 6.0 505 456 240 32 0.13 0.19 0.09




















ARB Dickstein 1995 2.0 56 56 9 2 0.21 0.77 0.02
min ARB Lang 1997 3.0 40 40 10 5 0.50 1.17 0.16
ARB ELITE I 1997 11.0 352 287 293 17 0.06 0.09 0.03
ARB STRETCH 1999 3.0 213 213 53 5 0.09 0.22 0.03
ARB SPICE 2000 3.0 179 148 41 6 0.15 0.32 0.05
ARB ELITE II 2000 24.0 1578 1453 3031 280 0.09 0.10 0.08
ARB REPLACE 2001 3.0 77 77 19 1 0.05 0.29 0.00
ARB HEAVEN 2002 3.0 70 65 17 1 0.06 0.33 0.00
ARB Mitrovic 2003 3.0 44 44 11 1 0.09 0.51 0.00
ARB RESOLVD 2003 6.0 126 122 57 12 0.21 0.37 0.11
ARB CHARM-alt 2003 42.0 1013 1013 3546 265 0.07 0.08 0.07
BB CARMEN 2004 18.0 191 134 244 14 0.06 0.10 0.03
BB CIBIS III 2008 6.0 505 470 244 23 0.09 0.14 0.06
ACEI + ARB Hamroff 1999 6.0 16 13 7 5 0.50 0.00 0.00
ACEI + ARB Val-HeFT 2001 27.0 2511 2511 5650 495 0.09 0.10 0.08
ACEI + ARB RESOLVD 2003 6.0 86 82 39 8 0.21 0.41 0.09
ACEI + BB CIBIS I 1994 26.0 320 245 612 53 0.09 0.11 0.06
ACEI + BB Krum 1995 3.5 33 29 9 3 0.33 0.97 0.07
ACEI + BB Colucci 1996 12.0 232 232 232 2 0.01 0.03 0.00
ACEI + BB PRECISE 1996 6.0 133 133 67 6 0.09 0.20 0.03
ACEI + BB Packer 1996 6.0 696 696 348 22 0.06 0.10 0.04
ACEI + BB MOCHA 1996 6.0 89 82 43 1 0.02 0.13 0.00
ACEI + BB Cohn 1997 6.0 70 66 34 2 0.06 0.21 0.01
ACEI + BB MERIT-HF 1999 12.0 1990 1711 1851 145 0.08 0.09 0.07
ACEI + BB Goldstein 1999 6.0 42 33 19 1 0.05 0.30 0.00
ACEI + BB CIBIS II 1999 46.0 1327 1327 5090 156 0.03 0.04 0.03
ACEI + BB MIC 2000 6.0 26 22 12 1 0.08 0.46 0.00
ACEI + BB Sturm 2000 24.0 51 28 79 5 0.06 0.15 0.02
ACEI + BB CELICARD 2000 12.0 66 48 57 2 0.04 0.13 0.00
ACEI + BB BEST 2001 42.0 1354 1349 4730 411 0.09 0.10 0.08
ACEI + BB COPERNICUS 2001 21.0 1156 1010 1896 130 0.07 0.08 0.06
ACEI + BB Cicoira 2002 12.0 52 46 49 4 0.08 0.21 0.02
ACEI + BB de Milliano 2002 6.0 43 39 21 4 0.20 0.50 0.05
ACEI + BB Dubach 2002 12.0 13 13 13 1 0.08 0.43 0.00
ACEI + BB CHARM-added 2003 42.0 1272 1272 4452 412 0.09 0.10 0.08
ACEI + BB SYMPOXYDEX 2004 6.0 28 26 14 1 0.07 0.41 0.00
ACEI + BB CARMEN 2004 18.0 191 132 242 14 0.06 0.10 0.03
ACEI + BB ENECA 2005 12.0 134 124 129 7 0.05 0.11 0.02
ACEI + BB Palazzuoli 2005b 12.0 32 30 31 1 0.03 0.18 0.00
ACEI + BB Palazzuoli 2005 12.0 33 31 32 1 0.03 0.17 0.00
ACEI + BB AREA-IN CHF 2009 12.0 236 236 236 12 0.05 0.09 0.03
ACEI + BB EMPHASIS-HF 2011 36.0 1373 1145 3777 213 0.06 0.06 0.05
ACEI + BB VIzzardi 2014 44.0 65 65 238 8 0.03 0.07 0.01
ARB + BB RESOLVD 2003 6.0 125 108 53 2 0.04 0.13 0.00
ACEI + MRA RALES 1999 24.0 822 600 1422 284 0.20 0.22 0.18
ACEI + ARB + BB RESOLVD 2003 6.0 89 77 38 6 0.16 0.34 0.06
ACEI + ARB + BB CHARM-added 2003 42.0 1276 1276 4466 377 0.08 0.09 0.08
ACEI + BB + MRA Cicoira 2002 12.0 54 47 51 3 0.06 0.17 0.01
ACEI + BB + MRA AREA-IN CHF 2009 12.0 231 231 231 6 0.03 0.06 0.01
ACEI + BB + MRA EMPHASIS-HF 2011 36.0 1364 1142 3759 171 0.05 0.05 0.04
ACEI + BB + MRA VIzzardi 2014 44.0 65 65 238 8 0.03 0.07 0.01
ACEI + BB + MRA PARADIGM-HF 2014 27.0 4212 4203 9467 835 0.09 0.09 0.08
ARNI + BB + MRA PARADIGM-HF 2014 27.0 4187 4176 9408 711 0.08 0.08 0.07






Supplementary Figure 3: Results of random effect network meta-analysis probability rank 
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